Abstract:Objective To evaluate the application of Warfarin genetic testing in individualized anticoagulant therapy for patients with non-valvular atrial fibrillation (NVAF). Methods NVAF patients undergoing Warfarin treatment at the Outpatient Department of Northern Jiangsu People′s Hospital between January 2021 and January 2023 were enrolled. According to whether Warfarin genetic testing was performed, they were divided into a genetic testing group and a routine follow-up group. The clinical data were collected, and adverse events were statistically analyzed. The two groups were compared in initial international normalized ratio (INR), time to achieve therapeutic INR, time to reach stable warfarin dose, percentage of time INR in therapeutic range (TTR) at different times, and adverse reactions. SPSS 27.0 was used for statistical analysis. Data comparison between two groups was performed using t test, Wilcoxon test,χ2 test or Fisher exact test depending on data type. Results A total of 200 patients were enrolled in this study, includ-ing 110 patients in the genetic testing group and 90 in the routine follow-up group. In the genetic testing group, 90.00% (99/110) were of AA wild type, 8.18% (9/110) of AC heterozygous, and 1.82% (2/110) of CC homozygous at the CYP2C9 3 locus; 86.36% (95/110) of AA mutation homozygous, 11.82% (13/110) of GA heterozygous, and 1.82% (2/110) of GG mutation homozygous for the VKORC1 gene. Minor bleeding occurred in two patients (1.81%) in the genetic testing group without major bleeding, and minor bleeding occurred in six patients (6.67%) and major bleeding in two patients (2.22%) in the routine follow-up group. There was no significant difference in the cumulative incidence of minor and major bleeding between the two groups (P>0.05) The time to reach the therapeutic INR was (28.09±31.21)d in the genetic testing group, and (45.47±45.33)d in the routine follow-up group, with a statistically significant difference (P<0.05). At one month, TTR in the genetic testing group was higher than that in the routine follow-up group, with a statistically significant difference (P<0.05), but there was no significant difference between the two groups at 3,6 and 12 months. The gene testing group had a notably lower incidence rate of INR<1.2 events and INR>3.5 events than the routine follow-up group, with a statistically significant difference (P<0.05). Conclusion Genetic testing can identify individual sensitivity to Warfarin, helping patients to reach target doses quickly and maintain INR within the optimal therapeutic range and thereby reducing the adverse events such as bleeding and thromboses.